Trials / Withdrawn
WithdrawnNCT06052423
ARTEMIS-007: HS-20093 in Patients With Extensive Stage Small Cell Lung Cancer
ARTEMIS-007: A Phase 2 Study to Evaluate Efficacy and Safety of HS-20093 in Patients With Extensive Stage Small Cell Lung Cancer
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Hansoh BioMedical R&D Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase 2,open-label, multi-center study to evaluate the efficacy, safety, pharmacokinetics (PK) and immunogenicity of HS-20093 as a monotherapy in patients with small cell lung cancer(SCLC).
Detailed description
Intravenous (IV) administration of HS-20093 Q3W; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and disease progression.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HS-20093 | HS-20093 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells. |
Timeline
- Start date
- 2024-11-30
- Primary completion
- 2025-06-30
- Completion
- 2027-06-30
- First posted
- 2023-09-25
- Last updated
- 2024-03-04
Source: ClinicalTrials.gov record NCT06052423. Inclusion in this directory is not an endorsement.